1. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina. Among patients with stable angina who were receiving little or no antianginal medication and had objective evidence of ischemia, PCI resulted in a lower angina symptom score than a placebo procedure, indicating a better health status with respect to angina.
2. Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al. Complete or culprit-only PCI in older patients with myocardial infarction. N Engl J Med 2023;389: 889–98. Among patients who were 75 years of age or older with myocardial infarction and multivessel disease, those who underwent physiology-guided complete revascularization had a lower risk of a composite of death, myocardial infarction, stroke, or ischemiadriven revascularization at 1 year than those who received culprit-lesion–only PCI.
3. Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, et al. Optical coherence tomographyguided versus angiography-guided PCI. N Engl J Med 2023;389:1466–76. Among patients undergoing PCI, OCT guidance resulted in a larger minimum stent area than angiography guidance, but there was no apparent between-group difference in the percentage of patients with targetvessel failure at 2 years.
4. Holm NR, Andreasen LN, Neghabat O, Laanmets P, Kumsars I, Bennett J, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med 2023;389: 1477–87. Among patients with complex coronaryartery bifurcation lesions, OCT-guided PCI was associated with a lower incidence of MACE at 2 years than angiography-guided PCI.
5. Kang J, Rizas KD, Park KW, Chung J, van den Broek W, Claassens DMF, et al. Dualantiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J 2023;44:1360–70. In this individual patient data meta-analysis, DAPT-based de-escalation was associated with both decreased ischaemic and bleeding endpoints. Reduction in bleeding endpoints was more prominent for the unguided than the guided de-escalation strategy.
6. Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal lifesupport in infarct-related cardiogenic shock. N Engl J Med 2023;389:1286–97. In patients with acute myocardial infarction complicated by cardiogenic shock with planned early revascularization, the risk of death from any cause at the 30-day followup was not lower among the patients who received extracorporeal life support therapy than among those who received medical therapy alone.
7. Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389: 1949–60. Among low-risk patients with severe, symptomatic aortic stenosis who underwent TAVI or surgery, there was no significant between-group difference in the two primary composite outcomes.
8. Sorajja P, Whisenant B, Hamid N, Naik H, MakkarR, TadrosP, etal. Transcatheterrepairfor patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–42. Tricuspid Transcatheter edge-to-edge repair was safe for patients with severe tricuspid regurgitation, reduced the severity of tricuspid regurgitation, and was associated with an improvement in quality of life.
9. Koeckerling D, Raguindin PF, Kastrati L, Bernhard S, Barker Jo, Quiroga Centeno AC, et al. Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis. Eur Heart J 2023;44:935–50. Certain devices may provide benefits in femoropopliteal disease, but comparative data in aortoiliac arteries is lacking. Gaps in evidence quantity and quality impede identification of the optimal endovascularapproach to intermittent claudication.
10. Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 trial. Lancet 2022;400: 1405–16. This final report of the SYMPLICITY HTN-3 trial adds to the totality of evidence supporting the safety of renal artery denervation to 36 months after the procedure. From 12 months to 36 months after the procedure, patients who were originally randomly assigned to receive renal artery denervation had larger reductions in blood pressure and better blood pressure control compared with patients who received sham control.
Accedi per leggere tutto l'articolo
Inserisci i dati del tuo account su Cardiotalk per accedere e leggere tutto il contenuto dell'articolo.
Se non hai un account, clicca sul pulsante registrati e verrai reindirizzato al portale Cardiotalk per la registrazione.
